Non-psychotropic cannabinoids in pain management: A comprehensive review of mechanisms, clinical evidence, and therapeutic potential

Abstract

Chronic pain represents a significant global health challenge, and the limitations of conventional analgesics have urged a search for alternative therapeutic strategies. Cannabinoids derived from Cannabis sativa have emerged as prominent candidates. While psychotropic cannabinoids are known for their analgesic effects, their psychoactive properties often limit their clinical utility. Consequently, interest has shifted towards non-psychotropic cannabinoids that offer potential pain relief without inducing cognitive or euphoric effects. This comprehensive review investigates the pain-modulating mechanisms of cannabinoids, encompassing interactions with the endocannabinoid system and other non-traditional pathways, and summarizes the existing preclinical and clinical evidence supporting their use in various pain states. Furthermore, it discusses the therapeutic potential, clinical considerations, significant challenges, and the need for product standardization. This review also aims to evaluate the role and prospects of non-psychotropic cannabinoids as a therapeutic option for pain management.

Keywords

Chronic pain / Non-psychotropic cannabinoids / Endocannabinoid system / Analgesic mechanisms / Pain management

Conflict of interest statement

The author declares that she has no conflicts of interest related to this work.

Funding

The article received no extramural funding.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Cohen SP, Vase L, Hooten WM. Chronic pain: An update on burden, best practices, and new advances. Lancet 2021; 397(10289): 2082-2097.

[2] Grant CH, Walker H, Barnett KN, Mark PB, Colvin LA, Bell S. Multimorbidity and analgesic-related harms: A systematic review. Br J Anaesth 2025; 134(6): 1717-1745.

[3] Cvijic A, Bauer B. History and medicinal properties of cannabis. Pharmacogn Rev 2024; 18(36): 159-164.

[4] Rezende B, Alencar AKN, de Bem GF, Fontes-Dantas FL, Montes GC. Endocannabinoid system: Chemical characteristics and biological activity. Pharmaceuticals (Basel) 2023; 16(2). doi: 10.3390/ph16020148.

[5] Lacerda M, Carona A, Castanheira S, Falcâo A, Bicker J, Fortuna A. Pharmacokinetics of non-psychotropic phytocannabinoids. Pharmaceutics 2025; 17(2). doi: 10.3390/pharmaceutics17020236.

[6] Li M, She K, Zhu P, Li Z, Liu J, Luo F, et al. Chronic pain and comorbid emotional disorders: Neural circuitry and neuroimmunity pathways. Int J Mol Sci 2025; 26(2). doi: 10.3390/ijms26020436.

[7] Anand U, Pacchetti B, Anand P, Sodergren MH. Cannabis-based medicines and pain: A review of potential synergistic and entourage effects. Pain Manag 2021; 11(4): 395-403.

[8] Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2018; 84(9): 1888-1900.

[9] Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J 2013; 4(4). doi: 10.5041/RMMJ.10129.

[10] Xu K, Wu L. Microglial cannabinoid CB₂ receptors in pain modulation. Int J Mol Sci 2023; 24(3). doi: 10.3390/ijms24032348.

[11] Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci 2018; 19(3). doi: 10.3390/ijms19030833.

[12] Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.

[13] Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain. Handb Exp Pharmacol 2015; 227: 119-143.

[14] Raïch I, Lillo J, Rivas-Santisteban R, Rebassa JB, Capó T, Santandreu M, et al. Potential of CBD acting on cannabinoid receptors CB₁ and CB₂ in ischemic stroke. Int J Mol Sci 2024; 25(12). doi: 10.3390/ijms25126708.

[15] Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 2019; 11. doi: 10.3389/fnmol.2018.00487.

[16] De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, et al. Cannabidiol modulates serotonergic transmission and reverses allodynia and anxiety-like behavior. Pain 2019; 160(1): 136-150.

[17] Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, et al. A randomized, double-blind, placebo-controlled study of topical cannabidiol for peripheral neuropathy. J Pain Res 2020; 13: 1001-1012.

[18] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and antiinflammatory properties of cannabidiol. Antioxidants 2019; 9(1). doi: 10.3390/antiox9010021.

[19] Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero C, et al. Cannabigerol action at CB₁ and CB₂ receptors. Front Pharmacol 2018; 9: 632.

[20] De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 2008; 325(3): 1007-1015.

[21] Godbole SS, Sun D, Coates MD, Himmelberger VJ, Roopchand DE, Raup-Konsavage WM. Orally administered CBD/CBG hemp extract reduces severity of ulcerative colitis and pain in a murine model. J Clin Med 2025; 14(17). doi: 10.3390/jcm14176095.

[22] Farrimond JA, Whalley BJ, Williams CM. Cannabinol and cannabidiol exert opposing effects on feeding patterns. Psychopharmacology (Berl) 2012; 223(1): 117-129.

[23] Bonn-Miller MO, Feldner MT, Bynion TM, Eglit GML, Brunstetter M, Kalaba M, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol 2024; 32(3): 277-284.

[24] Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, et al. The entourage effect. Curr Neuropharmacol 2020; 18(2): 87-96.

[25] Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain. Eur J Pain 2016; 20( 6): 936-948.

[26] Xu DH, Cullen BD, Tang M, Fang Y. Effectiveness of topical cannabidiol oil for peripheral neuropathy. Curr Pharm Biotechnol 2020; 21(5): 390-402.

[27] Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, et al. Cannabigerol: Molecular mechanisms and therapeutic potential. Molecules 2024; 29(22). doi: 10.3390/molecules29225471.

[28] Hunter D, Oldfield G, Tich N, Messenheimer J. Transdermal cannabidiol for knee osteoarthritis. Osteoarthr Cartil 2020; 28(Suppl 1): S275-S276.

[29] Xu DH, Cullen BD, Tang M, Fang Y. Topical cannabidiol in peripheral neuropathy. Curr Pharm Biotechnol 2020; 21(5): 390-402.

[30] Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 2018; 3(1): 152-161.

[31] Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of cannabigerol-predominant cannabis preparations. Cannabis Cannabinoid Res 2022; 7(5): 671-682.

[32] Capano A, Weaver R, Burkman E. Effects of cannabidiol and cannabinol in fibromyalgia. J Clin Rheumatol 2020; 26(7): 285-288.

[33] Mangoo S, Erridge S, Holvey C, Coomber R, Barros DAR, Bhoskar U, et al. Outcomes of medicinal cannabis therapy for depression. Expert Rev Neurother 2022; 22(11-12): 995-1008.

[34] Boehnke KF, Wu CL, Clauw DJ. Integrating cannabis into chronic pain treatment. Anesth Analg 2024; 138(1): 5-15.

[35] Nielsen S, Picco L, Murnion B, Winters B, Matheson J, Graham M, et al. Opioidsparing effect of cannabinoids for analgesia: An updated systematic review and metaanalysis of preclinical and clinical studies. Neuropsychopharmacology 2022; 47(7): 1315-1330.

[36] Silva Sá S, Melo-Alvim C, Reis-Pina P. Effects of cannabinoids on pain control, quality of life, and opioidsparing in cancer patients: systematic review. Brazilian J Pain 2023; 6( 3): 320-329.

[37] Zongo A, Herrera N, Lunghi C, El-Mourad J. Dosing of cannabinoids associated with an opioid-sparing effect: A systematic review of longitudinal studies. Pain Manag Nurs 2024; 25(1): e8-e20.

[38] Laczkovics C, Kothgassner OD, Felnhofer A, Klier CM. Cannabis and cannabidiol legal status. Pharmacopsychiatry 2021; 54(4): 163-171.

[39] Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA 2024; 331(22): 2267-2269.

[40] Shustorovich A, Corroon J, Wallace MS, Sexton M. Biphasic effects of cannabinoid therapy. Pain Med 2024; 25(6): 387-399.

[41] Nader FD, Lopes LPN, Ramos-Silva A, Matheus ME. Evidence of potential drug interactions between cannabidiol and other drugs: A scoping review to guide pharmaceutical care. Planta Med 2025; 91(9): 488-495.

[42] Bruni N, Della Pepa C, Oliveto F, Gigliano A, Berger M. Cannabinoid delivery systems. Molecules 2018; 23(10): 2478.

[43] Babayeva M, Loewy ZG. Cannabis pharmacogenomics: A path to personalized medicine. Curr Issues Mol Biol 2023; 45(4): 3479-3514.

[44] Blanton HL, Barnes RC, McHann MC, Bilbrey JA, Wilkerson JL, Guindon J. Sex differences and the endocannabinoid system in pain. Pharmacol Biochem Behav 2021; 202. doi: 10.1016/j.pbb.2021.173107.

[45] McParland AL, Bhatia A, Matelski J, Tian C, Diep C, Clarke H, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: A systematic review and metaanalysis of randomized controlled trials. Reg Anesth Pain Med 2023; 48(4): 180-190.

[46] Wu F, Ma Q, Tian G, Chen K, Yang R, Shen J. Formulation and evaluation of solid self-nanoemulsifying drug delivery system of cannabidiol for enhanced solubility and bioavailability. Pharmaceutics 2025; 17(3): 340.

[47] Dang A. Real-world evidence: A primer. Pharmaceut Med 2023; 37(1): 25-36.

[48] Vollert J, Kleykamp BA, Farrar JT, Gilron I, Hohenschurz-Schmidt D, Kerns RD, et al. Real-world data and evidence in pain research: A qualitative systematic review of methods in current practice. Pain Rep 2023; 8(2). doi: 10.1097/PR9.0000000000001057.

[49] Ngcobo NN. Silent dangers in elderly pharmacotherapy: The interplay of polypharmacy, multimorbidity, and drug interactions. J Eval Clin Pract 2025; 31(7). doi: 10.1111/jep.70283.

[50] Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, et al. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract 2021; 75(8). doi: 10.1111/ijcp.13871.

[51] Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. Cannabis-based pharmaceuticals in pain medicine. Pain Ther 2020; 9: 45-66.